influenza B, and type 1 parainfluenza viruses in chicken embryo cells was reduced by Virazole treatment. Recoverable intra-and extracellular virus titers were reduced by the drug in experiments with type 1 herpes, vaccinia, type 3 parainfluenza, and vesicular stomatitis viruses. Plaque formation by type 1 herpesvirus was also inhibited by exposure of the infected cells to Virazole. Pretreatment of cells with the compound, followed by its removal before addition of type 1 herpesvirus, severely lessened the antiviral activity; the compound was still moderately effective in reducing the viral effects on the cells when added as long as 22 hr after the virus. Parallel experiments, in which the antiviral activity of a number of known active drugs was compared, indicated Virazole to have at least a comparable degree of activity, and it was also active against a wider variety of viruses than any of these known active materials. The CCEDSo of Virazole to chicken embryo cells was approximately 1,000 ug/ml, although concentrations as low as 10 ig/ml caused slight (15%) inhibition in total cellular protein after 72 hr of incubation.
The rapidly expanding knowledge of viruses and the mechanisms whereby they infect cells and cause disease has induced investigators in recent years to direct considerable effort toward discovering drugs for control of virus diseases. Despite such efforts, few antiviral drugs exist today which have clinical value, and these (e.g., methisazone, idoxuridine, adamantane, arabinosyladenine, arabinosylcytosine) are active only against a relatively small spectrum of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) viruses. An exception to this lack of broad-spectrum antiviral activity is the group of interferon inducers, none of which has yet been shown to have clinical usefulness. No synthetic compounds are known which have significant in vitro and in vivo antiviral activity against both DNA and RNA viruses.
The design and synthesis of a new chemical which appears to be one of the first synthetic, non-interferon-inducing broad-spectrum antiviral agents was recently reported by Witkowski et al. (11) . A brief report summarizing the antiviral activity of this triazole nucleoside has been published by Sidwell et al. (10) . The 3 .0 X 10' RK-13 cells were seeded in 5-ml volumes in 60-mm plastic petri dishes (Falcon Plastics). After a 24-hr incubation at 37 C in a 5% CO2 atmosphere, the medium was removed, and duplicate cultures were nourished with 2 ml of MEM containing 0.1% NaHCO,, 5% FBS, and Virazole at concentrations of 1,000, 500, 100, 10, and 1 jg/ml. At 0, 24, 48, and 72 hr after addition of the drug, the medium was removed, 0.7 ml of 0.25% trypsin was added, and the cells were incubated at 37 C for 15 min. The cells were then gently scraped from the plates with a rubber policeman and suspended in 1. Cytotoxicity was also determined by microscope examination of the drug-exposed cell layers, with numbers of floating cells, cell granulation, and alteration of cell shape used as indications of toxicity. The latter visual examination procedure was that used in the majority of the viral chemotherapy experiments.
Total cell protein was determined by the method of Oyama and Eagle (5) . The cells were planted in plastic panels and allowed to grow overnight before being exposed to various concentrations of 
RESULTS
The results of a typical experiment to determine the effect of Virazole on the growth of RK-13 cells are shown in Fig. 1 . A definite decrease (from time zero) in number of viable cells was seen only at the 500 and 1,000 ,ug/ml levels of the drug, although the cell growth rate was inhibited in direct proportion to the Virazole concentration used at all levels tested. pg/ml.
The viral CPE-inhibitory activity of Virazole against all of the DNA and RNA viruses studied is summarized in Table 2 . Only PRV-, PV/2-, CV-, and RV/2-induced CPE were not signifi- on September 28, 2017 by guest http://aac.asm.org/ Downloaded from both intra-and extracellular virus titer ( Fig.  3-5) . Concentrations of the drug as low as 10 ,g/ml were effective in reducing the number of plaques produced by HSV/1 in RK-13 cells (Table 4) . In a timed experiment, Virazole significantly inhibited HSV/1 CPE when added as late as 22 5 hr after exposure of KB cells to the virus (Table  5 ). The activity of the compound began to decline at these later time intervals, however. If the cells were incubated with Virazole for 2 hr, the drug was removed, and the cells were washed prior to addition of the virus, the antiviral activity was markedly reduced. A comparison of the in vitro antiviral activity of several previously reported antiviral compounds with the activity of Virazole is summarized in In our own experience, as well as that of other investigators (4, 6) , it is important that the activity of an antiviral compound be determined in a number of cell systems, since that activity can be quite varied in dissimilar systems. The lesser degree of Virazole anti-DNA virus activity in Vero cells confirms this. In spite of the susceptibility of these cells to many viruses (3), the DNA virus inhibitory activity of Virazole may not have been discovered had Vero cells been used as the primary evaluation system. It is unclear why the drug is less active in these cells, although it may be speculated that they are producing a metabolite which at least partially blocks or reverses the antiviral activity of the compound.
The mode of antiviral action of Virazole was not fully explored in the present study. Other experiments have indicated that the drug is apparently not virucidal and that it is not an inducer of interferon (10) . The timing experiments indicate that the drug may be inhibiting an early stage of viral replication, although the effect on virus adsorption to, or penetration into, the cell was not explored in these experiments. The compound apparently must remain in contact with the cell to exert its antiviral action, since its removal from the medium surrounding the cell reverses its activity.
It is recognized that in vitro antiviral activity cannot be used as a major criterion to judge the eventual clinical applicability of a test chemical, since other investigations (1, 8) have demonstrated that a material active in cell culture may not be active in animal systems. It is significant, then, that the antiviral activity of Virazole has been confirmed in a variety of animal virus ex- periments (10) . Subsequent reports will further describe this in vivo activity.
